Advancing Guideline-Directed Medical Therapy in Heart Failure: Overcoming Challenges and Maximizing Benefits.
Zixi ZhangCancan WangTao TuQiuzhen LinJiabao ZhouYunying HuangKeke WuZeying ZhangWanyun ZuoNa LiuYichao XiaoQi Ming LiuPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2024)
The delayed titration of guideline-directed drug therapy (GDMT) is a complex event influenced by multiple factors that often result in poor prognosis for patients with heart failure (HF). Individualized adjustments in GDMT titration may be necessary based on patient characteristics, and every clinician is responsible for promptly initiating GDMT and titrating it appropriately within the patient's tolerance range. This review examines the current challenges in GDMT implementation and scrutinizes titration considerations within distinct subsets of HF patients, with the overarching goal of enhancing the adoption and effectiveness of GDMT. The authors also underscore the significance of establishing a novel management strategy that integrates cardiologists, nurse practitioners, pharmacists, and patients as a unified team that can contribute to the improved promotion and implementation of GDMT.
Keyphrases
- poor prognosis
- primary care
- heart failure
- healthcare
- long non coding rna
- end stage renal disease
- quality improvement
- case report
- newly diagnosed
- ejection fraction
- acute heart failure
- randomized controlled trial
- systematic review
- prognostic factors
- peritoneal dialysis
- palliative care
- left ventricular
- emergency department
- electronic health record
- bone marrow
- patient reported outcomes
- patient reported
- peripheral blood
- replacement therapy